🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522409-39-00
Authorised Phase I

Immune Cell Therapy for People with Early, Active Multiple Sclerosis

2025-522409-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Medizinische Hochschule Hannover
Sponsor type
Educational Institution
Therapeutic area
Nervous System Diseases
Decision date
24/07/2026
Enrollment target
10
Sites
Germany

Condition studied

Newly diagnosed highly-active Multiple Sclerosis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522409-39-00 on CTIS ↗ ← All trials in the EU